GILOTRIF vs RYBREVANT

Independent side-by-side comparison.

Rated against independent regulatory sources·Last updated August 21, 2026·How we rate

Possible drug interaction. GILOTRIF and RYBREVANT are different prescription medicines. Combining or switching between them can cause interactions — talk to a pharmacist or prescriber before making changes. This page is not medical advice.

Attribute	GILOTRIF	RYBREVANT
Rating	72/100	New
Pharmacy pays	—	—
Type	RX	RX
Active ingredient	AFATINIB DIMALEATE	AMIVANTAMAB-VMJW
Manufacturer	Boehringer Ingelheim	Janssen Biotech
Dosage forms	Tablet	Injectable
Drug class	—	—
Boxed warning	None	None
Treats	Non-Small-Cell Lung Carcinoma, Squamous Cell Carcinoma	Non-Small-Cell Lung Carcinoma

gilotrif rybrevant

Rating

72/100

New

Pharmacy pays

—

Type

Active ingredient

AFATINIB DIMALEATE

AMIVANTAMAB-VMJW

Manufacturer

Boehringer Ingelheim

Janssen Biotech

Dosage forms

Tablet

Injectable

Drug class

—

Boxed warning

None

Treats

Non-Small-Cell Lung Carcinoma, Squamous Cell Carcinoma

Non-Small-Cell Lung Carcinoma

Frequently asked questions

What is the difference between Gilotrif and Rybrevant?

Gilotrif contains Afatinib Dimaleate, while Rybrevant contains Amivantamab-Vmjw — they have different active ingredients.

Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.